Menu
Washingtoner
  • Home
  • Health
  • Books
  • Business
  • Technology
  • Artificial Intelligence
  • Lifestyle
  • Marketing
  • Daryl Guberman
Washingtoner

CCHR Urges FDA Overhaul to End Psychiatric Drug and Device Harms
Washingtoner/10275453

Trending...
  • Spokane: Flags Lowered for the Victims of the Longview Tragedy
  • AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
CCHR Urges FDA Overhaul
The Mental Health Watchdog calls for reforms to protect public safety, citing decades of antidepressant, electroshock, and psychedelic drug risks.

LOS ANGELES - Washingtoner -- The Citizens Commission on Human Rights International is calling for an overhaul of mental health agencies to eliminate potential conflicts of interest that may be putting patients at risk. The 55-year mental health industry watchdog said oversight should focus on the Food and Drug Administration (FDA), the agency tasked with ensuring the safety, efficacy, and security of drugs, biological products, and medical devices.

This reform is particularly urgent, CCHR says, given the FDA's ongoing failure to address critical issues, including the fact that it has yet to ban a skin electroshock device used as painful behavior modification on students with autism and intellectual and mental handicaps. In March 2024, the FDA announced that an electrical stimulation device (ESD) for behavior modification presents an "unreasonable and substantial risk of illness or injury." It called for submissions but has yet to issue a final order prohibiting it.[1] Meanwhile, children and adults continue to be subjected to it.

This is despite, as early as 2012, Juan Mendez, the United Nations Special Rapporteur on Torture said using this aversion therapy device constituted torture. According to a human rights lawyer, "The passage of electricity through anybody's body is clearly associated with pain and suffering."[2] Health agencies and psychiatric associations allow electroconvulsive therapy (ECT) to continue to be given to children and adolescents, as well as to any individual without their consent—a practice the UN also considers coercion and torture. No clinical trials have proven the safety and efficacy of ECT.[3]

CCHR has long advocated for the FDA to recognize the dangers of electroshock and to protect the public from the mass reliance upon antidepressants and other psychotropic drugs that pose significant health risks. The group says critical warnings about the link between antidepressants and increased suicidality and violent behavior have been ignored.

More on Washingtoner
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • A Foundational Claim in Human Secrecy Goes Public
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
  • Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026

CCHR is concerned about how psychedelic drug applications are advancing through the agency, which, if approved, may increase acts of violence in the community. In June 2024, the FDA granted "Breakthrough Therapy Designation" to the hallucinogen psilocybin as an adjunct to treat "major depressive disorder." The designation is usually reserved for drugs that substantially improve over existing therapies in treating severe or life-threatening conditions.[4] Earlier, the FDA published guidelines for researchers to meet challenges in designing psychedelic drug development programs. "Psychedelic drugs may produce psychoactive effects such as mood and cognitive changes, as well as hallucinations. As a result, there is the potential for abuse of these drugs, which is a drug safety issue," according to the FDA.[5]

The U.S. is already plagued by acts of senseless violence, including school and community shootings, committed by people taking or withdrawing from psychiatric drugs. Psychedelics, if approved, could add to this. For years, the links between antidepressants and suicidality or violent behavior were suppressed, as documented by CCHR and medical experts.

The breakthrough SSRI antidepressant, fluoxetine, was approved in December 1987. By 1991, sales of the drug had reached nearly $1 billion and 3.5 million patients had taken it. The Los Angeles Times reported that antidepressants had been dogged by controversy over it being linked to suicide, homicide and other violence. The campaign exposing its risks was spearheaded by CCHR, a watchdog group that was established by the Church of Scientology in 1969 to investigate and expose psychiatric violations of human rights, including the failure to properly inform about treatment risks and harm. Sales "would be substantially higher" were it not for this campaign, said Steven Gerber, a securities analyst with Bateman Eichler in Los Angeles. According to the LA Times, "The campaign, which included involvement in dozens of criminal and civil suits, has nonetheless been surprisingly successful, alarming both potential patients and their doctors and contributing to the halt in growth of the drug's sales in [1991]."[6]

CCHR's Freedom of Information Act requests, review of court documents and media investigation findings reveal a scandalous history of cover-up of adverse drug effects. According to documents obtained in litigation, as early as 1984, German regulators had expressed concerns about fluoxetine and an increased risk of suicidality—three years before it was approved for the U.S. market. In 1990, FDA officer, Dr. David Graham reviewed the clinical trials and warned of large-scale under-reporting of suicidality.[7] An initially undisclosed memo from an antidepressant manufacturer admitted a rate of suicide to be 5.6 times higher than for the older tricyclic antidepressant, imipramine.[8] Adverse effects within two years of the drug being approved had reached nearly double those for an older antidepressant that had been on the market for 20 years.[9]

More on Washingtoner
  • Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
  • Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
  • From Broken to Soaring Week 40
  • Tacoma Dome Welcomes Class of 2026
  • Finnish Political Satire Film Generates 10,000+ Cross-Platform Interactions Following Gandalf Parody Video Across TikTok, YouTube and Telegram

FDA officials continued to find suicide and violence to be of concern, such as Dr. Andrew Mosholder, an FDA Safety Reviewer, who provided his findings to the FDA, but these were not released publicly.[10] The brazen refusal to publicly acknowledge the risks came to a head in 2004 when the U.S. House Energy and Commerce Subcommittee on Oversight and Investigations began an investigation.[11] Shortly after, the FDA added a black box warning of suicidality to SSRI antidepressant packaging for those 18 and younger, extending this later to age 24.

CCHR says that a comprehensive review of the FDA's review, approval and monitoring process for psychotropic drugs and psychiatric devices is vital to safeguarding public health and ensuring the protection of patients.

Sources:

[1] www.cchrint.org/2024/03/29/fda-again-pursues-ban-on-behavioral-electroshock-device/; www.thesunchronicle.com/news/local_news/fda-moves-again-to-ban-controversial-shock-therapy-devices-used-by-rotenberg-center/article_5b3792d4-3dd0-5745-a92b-332edf69b33f.html
[2] web.archive.org/web/20120623234442/http://www.myfoxboston.com/story/18840703/2012/06/20/un-investigating-judge-rotenberg-centers-use-of-shocks
[3] www.wisnerbaum.com/defective-medical-device-injuries/ect/
[4] med.uth.edu/psychiatry/2024/06/03/fda-grants-breakthrough-therapy-designation-to-cyb003-a-deuterated-psilocybin-analog-being-investigated-as-an-adjunctive-treatment-for-major-depressive-disorder-mdd/
[5] www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
[6] www.latimes.com/archives/la-xpm-1992-01-08-fi-1610-story.html
[7] Joseph Glenmullen, M.D., Prozac Backlash, (New York, NY: Simon & Schuster, 2000) p. 162; www.wisnerbaum.com/our-successes/advocacy-campaigns/antidepressant-trials-adult-suicidality-data/
[8] Dr. Richard DeGrandpre, "Anti-depressants may be hazardous to your health," Hartford Advocate, 20 Aug 2002
[9] Craig McLaughlin, "The Perils of Prozac," San Francisco Bay Guardian, 16 May 1996
[10] www.cchrint.org/cchrs-exposure-of-antidepressant-risks-false-marketing-of-the-chemical-imbalance-theory/#_edn124
[11] "Barton, Greenwood Seek Info From FDA On Antidepressants," Rep. Barton's website, 24 Mar. 2004

Contact
Citizens Commission on Human Rights International
***@cchr.org


Source: Citizens Commission on Human Rights
Filed Under: Government

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Spokane: Egypt National Team to Hold Open Training Session at Gonzaga University Ahead of FIFA World Cup 2026™
  • Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
  • ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
  • P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
  • City of Spokane Launches New Webpage, Notice Document to Connect Residents with Eviction Prevention Resources
  • Tuckwell Machinery Launches New Range of Woodworking Machinery
  • A Brave Little Hero with Four Paws
  • Arux Group CEO Calls on Security Industry to End Hidden Subcontracting and White-Papering
  • Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation
  • Ecuador Freedom Launches First Scheduled Motorcycle Tour of Northern Peru's Lost Kingdoms
  • Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
  • Neuro Recovery Institute Showcases Emerging Immersive Neuro-Rehabilitation Technology at Clinical Innovation Open House
  • Community, Conservation & Waterwise Inspiration Bloom on June 6
  • Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
  • Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
  • CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
  • Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
  • AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
_catLbl0 _catLbl1

Popular on Washingtoner

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 149
  • Applicants Sought for the Tacoma Creates Advisory Board - 108
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • Spokane: SPD Air Support Unit Continues to be a Vital Tool for the Department
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • KLEKT Announces Appointment of Jay Kimpton to Board of Directors
  • Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating
  • As Pentagon Releases Ufo Files, Debut Ya Novel Predicted It All
  • ICTPBX Released: White-Label, Multi-Tenant Open Source PBX Platform for ITSPs

Similar on Washingtoner

  • Spokane: Significant Impacts to North-South Travel
  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
  • Tacoma Dome Welcomes Class of 2026
  • City of Tacoma Launches ‘Tidy-Up Tacoma: Summer 2026’ With Major Gateway Cleanup Effort
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • City of Tacoma Attracts More Affordable Housing to Proctor Neighborhood
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute